Plenty of experimentation is done, but the results are frustratingly vague owing to the inability to be sure about the metabolites themselves or what they’re doing. Massachusetts-based medical technology company ReviveMed has raised $1.5m to use artificial intelligence (AI) to find connections between existing drugs and diseases with no known solution. The research will focus on the reactions of proteins and metabolites, biomolecules that have greater variety than proteins. Past experiments have led to only a partial understanding of a small number of known metabolites. “AI is going to be able to identify new molecules in our bodies that are not yet identified,” says Revive CEO David Sinclair. The seed funding round was led by Rivas Capital.
Massachusetts-based medical technology company ReviveMed has raised $1.5m to use artificial intelligence (AI) to find connections between existing drugs and diseases with no known solution. The research will focus on the reactions of proteins and metabolites, biomolecules that have greater variety than proteins. Past experiments have led to only a partial understanding of a small number of known metabolites. “AI is going to be able to identify new molecules in our bodies that are not yet identified,” says Revive CEO David Sinclair. The seed funding round was led by Rivas Capital.